tiprankstipranks
Trending News
More News >
IGC Pharma (IGC)
:IGC
Advertisement

IGC Pharma (IGC) AI Stock Analysis

Compare
925 Followers

Top Page

IGC

IGC Pharma

(NYSE MKT:IGC)

Rating:54Neutral
Price Target:
$0.50
▲(35.14%Upside)
IGC Pharma's overall stock score is primarily impacted by weak financial performance and poor valuation metrics. However, technical analysis shows a moderately positive trend, and recent progress in Alzheimer's research presents a potential growth opportunity. The absence of earnings call data limits the analysis of recent management insights.
Positive Factors
Clinical Trials
IGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.
Growth Opportunities
The company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.
Market Potential
The large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.
Negative Factors
Market Risks
The large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma (IGC) vs. SPDR S&P 500 ETF (SPY)

IGC Pharma Business Overview & Revenue Model

Company DescriptionIGC Pharma (IGC) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of debilitating and life-altering medical conditions. The company's core focus is on leveraging its expertise in cannabinoid-based therapies to address unmet needs in areas such as Alzheimer’s disease, chronic pain, and other neurological disorders. IGC Pharma is dedicated to advancing its pipeline of proprietary research compounds and delivering effective solutions that improve patients' quality of life.
How the Company Makes MoneyIGC Pharma generates revenue through the development and commercialization of pharmaceutical products and therapies, particularly those based on cannabinoid compounds. The company's revenue streams include sales of its proprietary products, licensing agreements, and potential collaborations with other pharmaceutical entities. Additionally, IGC may engage in partnerships with research institutions and healthcare organizations to further its research and development efforts, which could result in milestone payments and royalties. These partnerships and collaborations are significant contributors to the company's earnings, enabling it to expand its market presence and enhance its product offerings.

IGC Pharma Financial Statement Overview

Summary
IGC Pharma faces significant financial challenges, characterized by declining revenues, persistent net losses, and negative cash flow. While the company maintains a manageable level of debt, its reliance on external financing and decreasing equity raise concerns about long-term sustainability.
Income Statement
45
Neutral
IGC Pharma's revenue has shown fluctuations with a recent decrease. Despite this, gross profit margins have improved, but the company continues to face significant net losses, as reflected in negative net profit and EBIT margins. The decline in revenue and persistent losses highlight challenges in profitability and growth.
Balance Sheet
55
Neutral
The company's balance sheet shows moderate leverage with a low debt-to-equity ratio. Equity has declined over the years, indicating reduced financial stability. However, the company maintains a positive equity ratio, suggesting some level of financial resilience despite the decreasing asset base.
Cash Flow
42
Neutral
IGC Pharma's cash flow analysis reveals consistent negative free cash flow, indicating challenges in generating cash. The operating cash flow to net income ratio remains negative, reflecting inefficiencies in converting income into cash. Financing activities have been a key source of cash, highlighting reliance on external funding.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue1.27M1.34M911.00K397.00K898.00K
Gross Profit619.00K733.00K442.00K194.00K113.00K
EBITDA-6.83M-9.16M-10.91M-14.78M-8.25M
Net Income-7.12M-13.00M-11.51M-15.02M-8.81M
Balance Sheet
Total Assets8.75M9.90M17.18M26.83M35.87M
Cash, Cash Equivalents and Short-Term Investments405.00K1.20M3.35M10.46M14.63M
Total Debt238.00K345.00K481.00K488.00K985.00K
Total Liabilities2.42M2.58M2.27M2.94M3.06M
Stockholders Equity6.33M7.32M14.91M23.89M32.80M
Cash Flow
Free Cash Flow-5.28M-5.71M-7.67M-8.20M-12.39M
Operating Cash Flow-4.79M-5.20M-7.05M-7.46M-10.80M
Investing Cash Flow-442.00K-317.00K-235.00K-742.00K3.39M
Financing Cash Flow4.45M3.52M100.00K4.14M14.69M

IGC Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.37
Price Trends
50DMA
0.32
Positive
100DMA
0.31
Positive
200DMA
0.33
Positive
Market Momentum
MACD
0.02
Negative
RSI
55.63
Neutral
STOCH
69.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.32, and above the 200-day MA of 0.33, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.63 is Neutral, neither overbought nor oversold. The STOCH value of 69.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IGC.

IGC Pharma Risk Analysis

IGC Pharma disclosed 40 risk factors in its most recent earnings report. IGC Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IGC Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$193.11M15.0442.38%8.53%-16.64%
61
Neutral
$784.79M3.6624.14%5.83%72.33%
61
Neutral
$770.05M-6.42%1.34%5.70%36.39%
54
Neutral
$33.46M-104.33%-5.50%56.57%
52
Neutral
$128.50M-55.95%-12.33%-738.00%
47
Neutral
$107.45M-17.87%-7.16%28.78%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IGC
IGC Pharma
0.37
-0.08
-17.78%
NNBR
NN
2.18
-1.90
-46.57%
RCMT
Rcm Technologies
26.13
6.51
33.18%
SPLP
Steel Partners Holdings
40.98
3.86
10.40%
TUSK
Mammoth Energy Services
2.67
-1.31
-32.91%
FIP
FTAI Infrastructure Incorporation
6.71
-3.08
-31.46%

IGC Pharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
IGC Pharma Highlights Alzheimer’s Research Progress
Positive
Jun 17, 2025

On June 17, 2025, IGC Pharma released an updated corporate presentation highlighting its clinical study advancements, which will be used in upcoming conferences and meetings with stakeholders. The presentation underscores the company’s progress in Alzheimer’s research, particularly with its IGC-AD1 drug candidate, which has undergone rigorous preclinical and regulatory reviews, showing promising results in reducing Alzheimer’s symptoms and meeting FDA standards.

The most recent analyst rating on (IGC) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025